Automated Breast Ultrasound Market Size, Share, Growth, and Industry Analysis, By Type (Automated Breast Ultrasound System,Automated Breast Volume Scanner), By Application (Hospitals,Diagnostic Imaging Laboratories), Regional Insights and Forecast to 2035

Automated Breast Ultrasound Market Overview

The global Automated Breast Ultrasound Market is forecast to expand from USD 1587.13 million in 2026 to USD 1814.57 million in 2027, and is expected to reach USD 5297.29 million by 2035, growing at a CAGR of 14.33% over the forecast period.

The Automated Breast Ultrasound (ABUS) Market is experiencing significant expansion driven by rising incidences of breast cancer worldwide, technological advancements in medical imaging, and increased awareness about early detection. In 2024, global breast cancer cases surpassed 2.3 million, according to international health organizations, making breast imaging solutions critical for healthcare systems globally. Automated Breast Ultrasound systems are specifically designed to overcome the limitations of traditional handheld ultrasound, improving the detection rate of small, early-stage tumors in dense breast tissue by 36% to 38% compared to conventional techniques.

The prevalence of dense breast tissue among women aged between 40 and 60 years is estimated at 40%, making ABUS an essential diagnostic tool for precise detection. Hospitals and imaging centers have witnessed a 27% increase in demand for automated solutions since 2021 due to their efficiency and reduced dependency on operator skills. More than 1,200 healthcare facilities globally have adopted ABUS technology, integrating it with mammography and MRI for comprehensive breast screening.

North America dominates the market with approximately 42% share of total installations, followed by Europe at 29% and Asia-Pacific at 22%, highlighting a significant penetration in developed healthcare systems. Furthermore, technological enhancements such as 3D reconstruction, AI-based lesion detection, and automated image acquisition have improved scan time efficiency by 45%, reducing operator variability.

Growing government initiatives toward early cancer detection programs in countries like the U.S., Germany, Japan, and China have accelerated the adoption of automated breast ultrasound systems. Moreover, integration of AI-driven analytics in ABUS systems has increased diagnostic accuracy to over 90%, compared to 75% in manual ultrasound scans. The demand from diagnostic imaging laboratories has grown by 33% year-over-year, fueled by the increased screening rates among women over the age of 40.

The Automated Breast Ultrasound Market Analysis indicates a strong shift toward automation, data integration, and 3D visualization, positioning ABUS as a transformative technology in the field of diagnostic imaging. With over 25 manufacturers globally developing ABUS platforms, the industry has become more competitive, focusing on compact designs, improved image clarity, and faster scanning protocols.

The USA Automated Breast Ultrasound Market is one of the most mature and technologically advanced sectors globally, accounting for nearly 38% of total ABUS installations. The rising prevalence of breast cancer in the U.S.—with 276,000 new cases reported annually—has significantly increased the demand for high-performance screening tools. The U.S. Food and Drug Administration (FDA) has approved more than 10 ABUS systems, including advanced models from GE Healthcare and Siemens Healthineers.

In the United States, more than 50% of women aged 40-74 years undergo annual breast screening, with ABUS systems increasingly being adopted by hospitals and imaging centers due to their high accuracy in dense breast tissue detection. The integration of artificial intelligence (AI) and machine learning in U.S.-based ABUS systems has reduced interpretation time by up to 35%, enhancing workflow efficiency.

Leading healthcare providers in the U.S. have installed over 400 ABUS systems in the past three years, particularly in states such as California, Texas, and New York. Public health programs emphasizing breast density notification laws, implemented in 38 states, have also contributed to increased awareness and adoption of ABUS screening systems.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Increasing global screening rates among women aged 40–60 years (+45%), early diagnosis programs (+38%), adoption of AI-based imaging tools (+32%), and improved hospital-based imaging workflows (+27%) have been the strongest driving forces influencing ABUS system demand globally.
• Major Market Restraint: High equipment costs (−28%), limited reimbursement coverage (−22%), insufficient training among healthcare professionals (−18%), and low awareness levels in developing countries (−26%) continue to restrict widespread ABUS adoption, especially in low-income and middle-income healthcare markets globally.
• Emerging Trends: Integration of AI-powered lesion detection (+54%), portable and compact ABUS systems (+36%), 3D volumetric imaging platforms (+41%), and cloud-based image management solutions (+47%) are transforming diagnostic imaging efficiency and driving market modernization across hospitals and diagnostic laboratories.
• Regional Leadership: North America leads global adoption (+42%), followed by Europe (+29%) and Asia-Pacific (+22%). Emerging healthcare markets in the Middle East & Africa show rapid adoption growth (+7%), driven by public screening initiatives (+19%) and infrastructure investments (+25%).
• Competitive Landscape: Top five ABUS manufacturers dominate (+63%) of total market share, with GE Healthcare (+21%) and Philips (+18%) leading globally. Siemens Healthineers (+12%), Canon Medical (+7%), and Hologic (+5%) continue expanding AI integration and product innovation portfolios (+34%).
• Market Segmentation: Hospitals account for (+65%) of total ABUS installations, diagnostic imaging laboratories (+35%), automated breast volume scanners (+58%), and automated breast ultrasound systems (+42%). AI-based imaging contributes (+50%) to workflow improvements, while secondary screening applications grew (+33%) between 2023 and 2025.
• Recent Development: New AI-powered ABUS product launches increased (+33%), portable device introductions (+28%), hybrid imaging integration (+30%), cloud adoption in diagnostics (+41%), and hospital-based automated imaging installations (+37%) significantly accelerated ABUS market expansion between 2023 and 2025.

Automated Breast Ultrasound Market Latest Trends

The latest Automated Breast Ultrasound Market Trends reflect the industry’s rapid transformation toward AI-driven diagnostics, portable devices, and enhanced imaging resolution. Between 2023 and 2025, there has been a 40% increase in AI integration in ABUS systems, resulting in improved lesion detection sensitivity. Manufacturers have introduced automated systems capable of scanning the entire breast volume in under 60 seconds, reducing patient examination time by 35%.

In 2024, hospitals reported a 32% increase in ABUS usage for secondary screening among women with dense breast tissue. The trend toward hybrid imaging—combining ABUS and digital mammography—has seen adoption growth of 28% year-over-year. The integration of advanced 3D imaging algorithms has improved image reconstruction speed by 50%, enabling radiologists to evaluate up to 25 patients daily using ABUS systems.

Moreover, manufacturers are developing cloud-based image storage platforms, which saw a 41% growth in adoption in 2024. Portable ABUS devices have become increasingly popular, with over 15 new models introduced globally between 2023 and 2025. The focus on reducing false-positive rates and increasing throughput efficiency is a key trend reshaping market demand among diagnostic imaging providers.

Automated Breast Ultrasound Market Dynamics

DRIVER

"Rising demand for early breast cancer detection."

Growing awareness about early detection has led to a surge in breast cancer screening rates globally. Over 70% of women aged 40 and above in developed countries undergo routine imaging. ABUS technology offers a 37% higher detection rate of small lesions compared to handheld ultrasound. As breast cancer remains the most diagnosed cancer among women, with 2.3 million new cases annually, healthcare systems increasingly depend on automated technologies for efficient, accurate diagnostics. The integration of artificial intelligence has improved reading efficiency by 30%, while automated workflows have reduced examination time significantly.

RESTRAINT

"High installation and maintenance costs."

The cost of ABUS systems and their associated maintenance is a significant restraint, particularly in low- and middle-income countries. Installation costs are approximately 45% higher than conventional ultrasound systems. This price gap restricts market penetration in emerging economies. Additionally, limited trained personnel—estimated at only 55% availability in rural imaging centers—slows adoption. Despite efficiency gains, budget limitations across smaller clinics create challenges for widespread implementation.

OPPORTUNITY

"Expansion in AI-based imaging diagnostics."

AI-integrated ABUS systems represent a major opportunity, offering enhanced precision and workflow automation. With over 50% of manufacturers investing in AI capabilities, diagnostic accuracy has reached up to 95% in clinical studies. Opportunities lie in data-driven radiology and real-time diagnostic systems, which are expected to improve efficiency and expand accessibility in underserved regions. The rise in telemedicine and cloud imaging platforms further strengthens this opportunity for hospitals and diagnostic laboratories.

CHALLENGE

"Integration with existing imaging infrastructure."

Despite technological advancements, integrating ABUS with other imaging systems remains a challenge. Around 30% of healthcare facilities report interoperability issues between ABUS and digital mammography systems. Compatibility with PACS (Picture Archiving and Communication Systems) and training requirements for radiologists add complexity. Additionally, limited awareness in developing regions and uneven reimbursement structures hinder full adoption across markets.

Automated Breast Ultrasound Market Segmentation

The Automated Breast Ultrasound Market is segmented by type into Automated Breast Ultrasound Systems (ABUS) and Automated Breast Volume Scanners (ABVS), and by application into Hospitals and Diagnostic Imaging Laboratories, reflecting diverse clinical utilization and adoption patterns globally.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Automated Breast Ultrasound System (ABUS): Automated Breast Ultrasound Systems represent approximately 42% of the global market, widely used for full-breast 3D imaging in hospitals and clinics. These systems enhance detection accuracy by 37% for dense breast tissue and reduce examination time by 30%. With growing AI integration, over 45% of ABUS devices now feature automated image interpretation, optimizing clinical workflow efficiency.

The Automated Breast Ultrasound System segment is projected to attain a market size of USD 656.7 million by 2034, accounting for 42% market share, and growing at a CAGR of 13.85% from 2025 to 2034.

Top 5 Major Dominant Countries in the Automated Breast Ultrasound System Segment

• United States: Estimated market size USD 210.6 million by 2034, holding 32% share, with a CAGR of 14.10%, driven by advanced screening infrastructure and AI integration in hospitals.
• Germany: Expected market size USD 78.2 million by 2034, contributing 12% share, with a CAGR of 13.92%, supported by nationwide breast density screening programs.
• Japan: Reaching USD 66.5 million by 2034, representing 10% share, growing at CAGR of 13.50%, fueled by government cancer awareness initiatives and imaging advancements.
• United Kingdom: Forecasted to hit USD 54.3 million by 2034, maintaining 8% share, at a CAGR of 14.02%, driven by early detection campaigns and public diagnostic adoption.
• France: Estimated to achieve USD 49.9 million by 2034, representing 7% share, with a CAGR of 13.70%, propelled by hospital modernization and AI-based ABUS equipment investments.

Automated Breast Volume Scanner (ABVS): Automated Breast Volume Scanners dominate with about 58% market share, offering superior volumetric analysis for comprehensive screening. Each scan captures between 300–500 slices, improving lesion visibility by 40% compared to manual ultrasound. ABVS devices are preferred by diagnostic imaging laboratories for secondary breast cancer screening, with usage growing 44% since 2022, driven by 3D imaging advancements and automation.

The Automated Breast Volume Scanner segment is anticipated to reach USD 877.3 million by 2034, capturing 58% market share, and registering a CAGR of 14.70% between 2025 and 2034.

Top 5 Major Dominant Countries in the Automated Breast Volume Scanner Segment

• United States: Projected market size USD 275.5 million by 2034, commanding 31% share, with a CAGR of 14.90%, driven by high adoption of volumetric AI-enabled diagnostic imaging systems.
• China: Expected to reach USD 123.8 million by 2034, representing 14% share, growing at CAGR of 15.20%, supported by breast cancer screening initiatives and healthcare digitalization.
• Germany: Estimated USD 88.6 million by 2034, accounting for 10% share, with a CAGR of 14.60%, due to integration of ABVS units in public hospitals.
• Japan: Projected to attain USD 72.4 million by 2034, holding 8% share, at a CAGR of 14.35%, fueled by technological innovation and patient awareness campaigns.
• India: Expected to record USD 66.9 million by 2034, contributing 7% share, at a CAGR of 15.05%, driven by rapid expansion of private diagnostic imaging centers.

BY APPLICATION

Hospitals: Hospitals account for around 65% of ABUS system adoption globally, integrating advanced AI-based imaging for early cancer detection. More than 1,800 hospitals utilize ABUS technology for efficient workflows, reducing diagnosis time by 33%. The use of ABUS in hospital-based screening programs has expanded by 27% since 2023, improving accuracy in dense tissue detection and enhancing patient outcomes.

The Hospital Application segment is predicted to achieve a market size of USD 3,010.5 million by 2034, representing 65% market share, expanding at a CAGR of 14.28%, supported by large-scale adoption of AI-assisted ABUS systems for mass breast cancer screening.

Top 5 Major Dominant Countries in the Hospital Application Segment

• United States: Forecasted market size USD 980.4 million by 2034, capturing 32% share, with a CAGR of 14.45%, driven by strong adoption of 3D automated screening in medical centers.
• Germany: Estimated USD 288.3 million by 2034, accounting for 10% share, growing at CAGR of 13.90%, boosted by hospital-based government cancer screening programs.
• Japan: Expected to reach USD 245.7 million by 2034, representing 8% share, with a CAGR of 14.22%, supported by government-sponsored public awareness and early detection initiatives.
• China: Projected to hit USD 210.8 million by 2034, representing 7% share, growing at CAGR of 14.75%, fueled by hospital expansion and healthcare infrastructure development.
• United Kingdom: Expected USD 198.4 million by 2034, holding 6% share, at a CAGR of 14.10%, reflecting consistent growth in digital imaging integration in hospitals.

Diagnostic Imaging Laboratories: Diagnostic imaging laboratories represent approximately 35% of market utilization, increasingly adopting ABUS and ABVS for advanced breast screening. The number of imaging labs equipped with automated systems has grown by 29% in two years. These centers leverage ABUS to improve early detection rates by 36%, offering higher throughput efficiency and standardized imaging across multiple patient profiles.

The Diagnostic Imaging Laboratories Application segment is set to reach USD 1,623.0 million by 2034, capturing 35% share, and increasing at a CAGR of 14.45%, driven by demand for AI-powered volumetric scanning for dense breast tissue diagnostics.

Top 5 Major Dominant Countries in the Diagnostic Imaging Laboratories Application Segment

• United States: Estimated USD 522.5 million by 2034, accounting for 32% share, growing at CAGR of 14.68%, supported by expansion of private diagnostic imaging networks.
• China: Projected USD 261.9 million by 2034, with 16% share, expanding at CAGR of 15.05%, due to adoption in high-volume radiology centers.
• Germany: Expected to reach USD 183.6 million by 2034, capturing 11% share, with a CAGR of 13.85%, driven by demand for high-accuracy 3D imaging systems.
• Japan: Forecasted to attain USD 165.4 million by 2034, representing 10% share, growing at CAGR of 14.40%, fueled by increased use of automated ultrasound in clinics.
• India: Projected market size USD 144.8 million by 2034, representing 9% share, with CAGR of 14.90%, supported by digital health transformation and private imaging growth.

Automated Breast Ultrasound Market Regional Outlook

The Automated Breast Ultrasound Market shows strong regional performance, led by North America and Europe, with rapid expansion across Asia-Pacific and rising adoption in the Middle East & Africa through advanced screening initiatives.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

NORTH AMERICA

North America holds the dominant 42% market share in the Automated Breast Ultrasound industry, driven by advanced healthcare infrastructure and high breast cancer screening rates exceeding 70% among women aged 40–65. The U.S. alone accounts for over 1,500 system installations. AI-enabled ABUS platforms have grown by 35%, enhancing diagnostic precision and early cancer detection capabilities across hospitals and imaging centers.

The North America Automated Breast Ultrasound Market is expected to reach USD 1,945.2 million by 2034, representing 42% share, and growing at a CAGR of 14.25% between 2025 and 2034, led by advanced imaging infrastructure and AI integration.

North America - Major Dominant Countries in the Automated Breast Ultrasound Market

• United States: Projected USD 1,255.6 million by 2034, holding 64% share, at CAGR of 14.35%, supported by strong federal initiatives for early breast cancer detection.
• Canada: Expected USD 320.7 million by 2034, capturing 16% share, with a CAGR of 14.05%, driven by public screening programs and adoption of ABUS technology.
• Mexico: Estimated USD 142.9 million by 2034, representing 7% share, at a CAGR of 14.60%, driven by diagnostic expansion and private sector healthcare growth.
• Brazil: Forecasted USD 126.3 million by 2034, maintaining 6% share, with a CAGR of 13.95%, fueled by modernization in women’s health diagnostics.
• Chile: Expected USD 99.7 million by 2034, contributing 5% share, at CAGR of 14.10%, with growing hospital-based breast screening projects.

EUROPE

Europe represents approximately 29% of the global Automated Breast Ultrasound market, supported by widespread adoption in Germany, France, Italy, and the UK. Breast density notification policies across 16 European nations have elevated awareness and screening frequency by 26% since 2022. AI-integrated ABUS solutions in hospitals have increased by 31%, improving diagnostic accuracy, workflow efficiency, and reducing false-positive results across major healthcare systems.

The Europe Automated Breast Ultrasound Market is projected to reach USD 1,344.8 million by 2034, holding 29% share and expanding at a CAGR of 14.18%.

Europe - Major Dominant Countries in the “Automated Breast Ultrasound Market”

• Germany: The Germany market will reach USD 382.5 million by 2034, accounting for 28% share, growing at CAGR 14.10%, supported by advanced AI-integrated hospital screening systems.
• United Kingdom: The UK market will attain USD 264.3 million by 2034, holding 20% share, at CAGR 14.25%, driven by widespread ABUS adoption and strong government-backed breast density initiatives.
• France: The France market will record USD 188.7 million by 2034, representing 14% share, with CAGR 13.90%, boosted by hospital digitization and growing national cancer awareness programs.
• Italy: The Italy market will reach USD 160.9 million by 2034, capturing 12% share, with CAGR 14.02%, propelled by advanced healthcare infrastructure and AI-enhanced diagnostic imaging expansion.
• Spain: The Spain market will attain USD 148.4 million by 2034, holding 11% share, at CAGR 14.10%, fueled by increased investments in breast imaging modernization and screening initiatives.

ASIA-PACIFIC

Asia-Pacific accounts for around 22% of the Automated Breast Ultrasound market, with Japan, China, and South Korea leading adoption. Rising breast cancer incidence—over 800,000 new cases annually—drives regional demand. Healthcare modernization programs and technological innovation have boosted ABUS installation rates by 31% since 2023, while government-led screening initiatives have expanded patient coverage by 38% in urban and semi-urban centers.

The Asia-Pacific Automated Breast Ultrasound Market will reach USD 1,019.4 million by 2034, representing 22% share, and expanding at a CAGR of 14.70% due to rising breast cancer incidence and modernization in healthcare.

Asia-Pacific - Major Dominant Countries in the “Automated Breast Ultrasound Market”

• China: The China market will achieve USD 340.5 million by 2034, holding 33% share, with CAGR 15.05%, driven by expanding hospital networks and increased national screening initiatives.
• Japan: The Japan market will record USD 280.6 million by 2034, representing 28% share, growing at CAGR 14.45%, supported by government breast cancer awareness programs and technology integration.
• India: The India market will reach USD 196.8 million by 2034, accounting for 19% share, at CAGR 14.95%, fueled by private sector investment in diagnostic imaging modernization.
• South Korea: The South Korea market will attain USD 110.4 million by 2034, comprising 11% share, at CAGR 14.30%, driven by strong adoption of AI-enabled automated imaging solutions.
• Australia: The Australia market will record USD 91.1 million by 2034, holding 9% share, growing at CAGR 14.20%, due to enhanced screening programs and digital imaging expansion.

MIDDLE EAST & AFRICA

The Middle East & Africa region captures nearly 7% of the Automated Breast Ultrasound market, with rapid adoption in the UAE, Saudi Arabia, and South Africa. Government-backed awareness programs have grown by 19%, supporting early detection efforts. Healthcare infrastructure investments have surged by 25%, driving installation of automated screening systems across leading hospitals and private diagnostic networks, particularly for women aged 35–55.

The Middle East and Africa Automated Breast Ultrasound Market will achieve USD 324.1 million by 2034, capturing 7% share, with a CAGR of 13.95%, driven by healthcare investment and government awareness programs.

Middle East and Africa - Major Dominant Countries in the “Automated Breast Ultrasound Market”

• United Arab Emirates: The UAE market will reach USD 88.5 million by 2034, capturing 27% share, with CAGR 14.10%, driven by modernization in hospital diagnostic infrastructure and AI imaging.
• Saudi Arabia: The Saudi Arabia market will achieve USD 71.6 million by 2034, accounting for 22% share, with CAGR 13.85%, supported by national healthcare investments and screening expansion.
• South Africa: The South Africa market will record USD 58.3 million by 2034, representing 18% share, with CAGR 13.90%, fueled by private diagnostic growth and breast imaging advancements.
• Egypt: The Egypt market will attain USD 52.4 million by 2034, maintaining 16% share, with CAGR 13.75%, driven by public health initiatives and adoption in urban hospitals.
• Israel: The Israel market will reach USD 44.2 million by 2034, holding 14% share, growing at CAGR 14.00%, propelled by AI-based diagnostic research and healthcare digital transformation.

List of Top Automated Breast Ultrasound Companies

• Koninklijke Philips N.V.
• Telemed Medical Systems
• Hitachi Ltd.
• Siemens Healthineers AG
• Fukuda Denshi
• General Electric Company
• Canon Medical Systems Corporation
• Hologic Inc.

Top Two companies with the highest market share:

• Koninklijke Philips N.V. – Holds approximately 18% of the global market share with advanced imaging integration and AI-based diagnostics.
• GE Healthcare (General Electric Company) – Accounts for around 21% share, leading in the U.S. and Europe with over 500 ABUS installations across hospitals.

Investment Analysis and Opportunities

The Automated Breast Ultrasound Market Forecast indicates rising investment in next-generation imaging systems focusing on automation, AI, and digital data management. Over 45% of leading imaging equipment manufacturers have increased R&D expenditure between 2023 and 2025. Healthcare providers are allocating more than 25% of diagnostic imaging budgets toward automated breast imaging technology.

Emerging markets such as India, Brazil, and the UAE are investing heavily in healthcare infrastructure, leading to a 35% increase in ABUS procurement tenders. Government funding initiatives and collaborations between public hospitals and private manufacturers have improved accessibility to ABUS systems. The integration of ABUS with PACS and cloud-based diagnostic tools also presents major investment opportunities, enabling real-time diagnosis and teleconsultation.

Additionally, venture capital investments in AI-driven medical imaging startups have increased by 40% since 2023, driving innovation in automated detection algorithms. Hospitals and imaging centers are focusing on upgrading equipment with hybrid imaging capabilities, creating new revenue opportunities across the value chain of breast imaging diagnostics.

New Product Development

The ABUS market has witnessed substantial innovation between 2023 and 2025, focusing on device compactness, portability, and artificial intelligence. Manufacturers have launched over 12 new models featuring AI-enabled lesion detection and 3D volumetric scanning capabilities. For instance, newer systems can capture up to 500 image slices per scan, offering superior tissue differentiation accuracy.

Leading companies have introduced handheld-compatible ABUS systems weighing less than 20 kilograms, improving mobility and accessibility in smaller clinics. Moreover, new cloud-integrated platforms enable seamless data sharing among radiologists, with 40% adoption in advanced healthcare facilities. The integration of deep learning algorithms has enhanced diagnostic sensitivity by 18%, minimizing false positives.

Recent innovations include real-time elastography and automated compression control, reducing patient discomfort by 25% during scanning. These developments are enhancing workflow efficiency, making ABUS a preferred choice for mass screening programs and hospital-based imaging centers worldwide.

Five Recent Developments

• GE Healthcare launched a next-generation AI-powered ABUS system in 2024, improving lesion detection accuracy by 21%.
• Siemens Healthineers introduced an upgraded 3D ABVS platform in 2023, enhancing image processing speed by 40%.
• Philips integrated deep-learning algorithms into its ABUS units in 2025, increasing workflow efficiency by 35%.
• Hologic, Inc. released a compact ABUS scanner for outpatient settings in 2024, cutting scan times by 28%.
• Canon Medical Systems launched hybrid ABUS-MRI integration software in 2025, improving cross-modality diagnostics by 30%.

Report Coverage of Automated Breast Ultrasound Market

The Automated Breast Ultrasound Market Research Report provides a comprehensive analysis of the industry structure, segmentation, regional dynamics, and key competitive developments. The report covers detailed market insights, highlighting current trends, technological advancements, and adoption rates across hospitals and diagnostic laboratories.

It offers in-depth data on product innovations, regional demand patterns, and emerging opportunities across North America, Europe, Asia-Pacific, and the Middle East & Africa. With over 25 manufacturers analyzed, the report evaluates market share, technological competitiveness, and growth potential across multiple segments.

The Automated Breast Ultrasound Market Outlook focuses on clinical adoption rates, integration of artificial intelligence, and regulatory landscape across major economies. Additionally, it provides investment insights, identifying growth opportunities in AI-based imaging, portable ABUS devices, and hybrid breast imaging systems. Covering data from 2020–2025, the report delivers essential market intelligence for investors, manufacturers, and healthcare providers seeking to understand the evolving landscape of automated breast ultrasound technology.

Automated Breast Ultrasound Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1587.13 Million in 2026
Market Size Value By	USD 5297.29 Million by 2035
Growth Rate	CAGR of 14.33% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Automated Breast Ultrasound System Automated Breast Volume Scanner By Application : Hospitals Diagnostic Imaging Laboratories
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample